Abstract
Non-Muscle-Invasive Urothelial Carcinoma of the Bladder (NMIBC) accounts for 70-80% of all Bladder Cancer initial diagnoses. The standard treatment for NMIBC involves transurethral resection of the tumor, followed by intravesical immunotherapy with BCG. The clinical benefits of BCG therapy have been extensively documented. However, only 50% of the patients have long-lasting benefit, where…